Qiagen

Corporate brand

A global provider of sample preparation, molecular testing and bioinformatics technologies for diagnostics, research and applied testing.

Last updated August 31, 2026

AI crawler reads

2requests

1companies

Anthropic2

Profile: 2
Controversies: 0
JSON · MD: 0

First read: Nov 4, 2026
Latest read: Nov 4, 2026

From this site's server log

Overview

Qiagen is a biotechnology and life-science company founded in Germany in 1984 and headquartered corporately in Venlo, the Netherlands. It develops and sells technologies used to collect, purify, amplify, analyze and interpret biological molecules, particularly nucleic acids such as DNA and RNA. Its customers include clinical laboratories, hospitals, pharmaceutical and biotechnology companies, universities, government agencies, forensic laboratories and other testing organizations. The company’s business is organized around sample technologies, molecular diagnostics, applied testing and products for pharmaceutical and academic research. Its sample-preparation portfolio includes manual and automated systems for extracting DNA and RNA from blood, tissue, saliva, microbial cultures, environmental samples and other materials. These technologies are used as upstream steps in workflows such as polymerase chain reaction, sequencing, genotyping, mutation analysis and infectious-disease testing. Qiagen also supplies enzymes, assay components, consumables, instruments and software that support complete laboratory workflows rather than isolated reagents. Qiagen became known early for making nucleic-acid purification more standardized and accessible. Its first product, introduced in 1986, was a kit for purifying plasmid DNA from bacterial cells. The company subsequently expanded through internal development and acquisitions into molecular diagnostics, quantitative PCR, digital PCR, next-generation sequencing, bioinformatics and clinical interpretation. Important additions included Digene’s human papillomavirus testing business, DxS’s personalized-healthcare technologies, Cellestis’s QuantiFERON tuberculosis testing platform, Ingenuity Systems, CLC bio, STAT-Dx, NeuMoDx and other specialized businesses. Its diagnostics portfolio includes tests and platforms for infectious diseases, oncology, women’s health, gastrointestinal disease and other clinical applications. QIAGEN’s QuantiFERON products are used in tuberculosis infection testing, while QIAstat-Dx provides multiplex syndromic testing through an automated molecular-diagnostics platform. The company has also developed QIAcuity digital PCR systems, QIAamp and related sample-preparation products, GeneReader sequencing technologies, and Qiagen Clinical Insights software for interpreting complex genomic information. Qiagen serves customers through a multinational operating structure with offices and regional organizations in Europe, the United States, China and the Asia-Pacific region. Its corporate headquarters are in Venlo, the main operational headquarters are in Hilden, and regional headquarters include locations in the United States, Shanghai and Singapore. The company operates in more than 25 countries and sells into a substantially broader global customer base. In 2020, Qiagen became the subject of a proposed acquisition by Thermo Fisher Scientific. The offer was increased after shareholder criticism but failed to reach the required acceptance threshold and was terminated in August 2020. Qiagen remained independent and subsequently consolidated its ownership of NeuMoDx. In later years it continued to build capabilities in enzymes, automated molecular testing, digital PCR, clinical interpretation and forensic or genetic-identification applications. Today, the brand is positioned as an integrated molecular-workflow provider combining consumables, instruments, assays and data analysis for both research and clinical use.

History

Qiagen was established on November 29, 1984, by scientists associated with Heinrich Heine University Düsseldorf in Germany. The company initially concentrated on making molecular-biology procedures more practical and reproducible. In 1986 it introduced its first product, a kit for purifying plasmid DNA from bacterial cells. This type of sample-preparation technology became the foundation for a broader business supplying reagents and systems used before amplification, sequencing and other forms of molecular analysis. The company expanded internationally and entered public markets during the 1990s. In 1996, Qiagen became the first German company to complete an initial public offering on the technology-oriented Nasdaq exchange. It followed with a Frankfurt Stock Exchange listing in 1997. These listings supported the company’s development from a specialist laboratory supplier into a multinational provider of molecular workflows. During the 2000s, Qiagen broadened its portfolio through acquisitions and geographic expansion. It acquired assets of Molecular Staging in 2004 and established an Asia regional headquarters in Shanghai in 2006. The 2007 acquisition of Digene for approximately $1.6 billion significantly increased Qiagen’s presence in molecular diagnostics, particularly testing associated with human papillomavirus and disease prevention. By 2007, the company reported sales of approximately $649.8 million and employed more than 2,600 people. Qiagen accelerated its move into personalized healthcare and clinical testing in 2009 through the acquisitions of DxS and SABiosciences. DxS brought technologies relevant to mutation testing and targeted therapies, while SABiosciences added gene-expression and pathway-analysis capabilities. Qiagen also released a clinically validated test for the H1N1 influenza virus during the global swine-flu outbreak. The company reported more than $1 billion in revenue and over 3,500 employees during that period. Further acquisitions added near-patient testing, hematological oncology, tuberculosis testing and bioinformatics. ESE GmbH was acquired in 2010 for point-of-need testing capabilities. In 2011, Qiagen bought Ipsogen, strengthening its blood-cancer diagnostics portfolio, and Cellestis, which provided the QuantiFERON tuberculosis testing technology. That year the company also announced a restructuring program aimed at concentrating resources on personalized medicine and emerging markets; the plan affected approximately 10% of its workforce at the time. In 2013 Qiagen acquired Ingenuity Systems and CLC bio, expanding its capabilities in biological-data interpretation and sequencing analysis. In 2015 it added circulating-tumor-cell technology from AdnaGen, enzyme capabilities and Mo Bio Laboratories. It also divested its Marseille operation through a management buyout that led to the formation of HalioDx. The GeneReader next-generation sequencing system was launched later in 2015. Exiqon, a Danish molecular-diagnostics company, was acquired in 2016, followed by OmicSoft in 2017, adding curated datasets and research-analysis tools. Qiagen transferred its United States listing from Nasdaq to the New York Stock Exchange in 2018. That year it acquired STAT-Dx of Spain and launched the QIAstat-Dx platform, an automated system for multiplex molecular testing. In 2019 the company announced an agreement involving Formulatrix assets to support digital PCR development and acquired N-of-One, a company specializing in clinical interpretation of complex genomic data. It also entered a non-exclusive agreement with Illumina to develop and commercialize in-vitro diagnostic kits for use with Illumina diagnostic instruments. In 2020 Thermo Fisher Scientific proposed acquiring Qiagen. The original offer was criticized by a major shareholder as too low and was subsequently increased. The transaction nevertheless failed to obtain the required shareholder acceptance and was terminated on August 13, 2020. Qiagen was required to reimburse Thermo Fisher for specified transaction expenses. Following the failed transaction, Qiagen acquired the remaining 80.1% of NeuMoDx Molecular that it did not already own, strengthening its automated PCR platform portfolio. In 2022 Qiagen acquired a majority stake in BLIRT, adding research and manufacturing capabilities for recombinant enzymes and molecular-biology reagents. In January 2023 it announced plans to acquire Verogen for approximately $150 million, a transaction that included the GEDmatch genetic-genealogy service and expanded the company’s exposure to forensic and human-identification applications. Across these stages, Qiagen evolved from a sample-preparation specialist into an integrated provider of molecular diagnostics, life-science research tools, applied testing systems and genomic interpretation software.

2023
Verogen acquisition announced
[1]Qiagenen.wikipedia.org
Qiagen announced plans to acquire Verogen and the GEDmatch genetic-genealogy service.
2022
BLIRT majority stake acquired
[1]Qiagenen.wikipedia.org
The transaction added enzyme-development and manufacturing capabilities.
2020
Thermo Fisher acquisition offer fails
[1]Qiagenen.wikipedia.org
The proposed acquisition was terminated after failing to meet the required shareholder-acceptance threshold.
2018
QIAstat-Dx platform launched
[1]Qiagenen.wikipedia.org
Following the STAT-Dx acquisition, Qiagen launched the QIAstat-Dx molecular-diagnostics platform.
2015
GeneReader system launched
[1]Qiagenen.wikipedia.org
Qiagen introduced its GeneReader next-generation sequencing system.
2011
Cellestis and Ipsogen acquisitions
[1]Qiagenen.wikipedia.org
The acquisitions added QuantiFERON tuberculosis testing and blood-cancer diagnostic capabilities.
2009
Personalized-healthcare expansion
[1]Qiagenen.wikipedia.org
Qiagen acquired DxS and SABiosciences and introduced an H1N1 diagnostic test.
2007
Digene acquisition
[1]Qiagenen.wikipedia.org
The acquisition expanded Qiagen’s molecular-diagnostics and disease-prevention business.
1997
Frankfurt Stock Exchange listing
[1]Qiagenen.wikipedia.org
Qiagen listed shares on the Frankfurt Stock Exchange.
1996
Nasdaq initial public offering
[1]Qiagenen.wikipedia.org
Qiagen became the first German company to complete an IPO on Nasdaq.
1986
First plasmid-DNA purification kit introduced
[1]Qiagenen.wikipedia.org
The company launched its first product for purifying plasmid DNA from bacterial cells.
1984
Company founded in Germany
[1]Qiagenen.wikipedia.org
Qiagen was established by scientists associated with Heinrich Heine University Düsseldorf.

Products and positioning

A quality- and workflow-focused molecular-biology partner serving clinical diagnostics, life-science research, pharmaceutical development and applied testing. Qiagen differentiates through integrated sample preparation, assay, instrument and bioinformatics offerings.

Sample preparation
QIAamp
QIAamp is a major family of silica-based nucleic-acid purification products. The range supports extraction of DNA or RNA from biological specimens such as blood, tissue, saliva, microbial samples and other matrices. Products are offered in manual and automated formats and are commonly used as the front end of PCR, sequencing, genotyping and molecular-diagnostic workflows.
Digital PCR
QIAcuity
QIAcuity is Qiagen’s digital PCR platform for highly sensitive nucleic-acid quantification. It partitions samples into many individual reactions and uses endpoint detection to measure targets with applications in mutation analysis, copy-number assessment, gene-expression work and pathogen detection. The platform combines instrumentation, consumables and analysis software.
Molecular diagnostics · 2018
QIAstat-Dx
QIAstat-Dx is an automated syndromic molecular-diagnostics platform. It is designed to test clinical specimens for multiple pathogens or targets in a single run, helping laboratories use standardized cartridge-based workflows. The system was developed following Qiagen’s acquisition of STAT-Dx and is associated with respiratory, gastrointestinal and other diagnostic panels.
Infectious-disease diagnostics
QuantiFERON
QuantiFERON is Qiagen’s interferon-gamma release assay family, best known for testing immune responses associated with tuberculosis infection. It provides an alternative to some traditional skin-test approaches and is used by clinical laboratories, public-health organizations and occupational-health programs. The platform originated with Cellestis, acquired by Qiagen in 2011.
Next-generation sequencing · 2015
GeneReader NGS System
The GeneReader NGS System was Qiagen’s integrated next-generation sequencing workflow, combining library preparation, sequencing and downstream analysis. It was aimed particularly at targeted sequencing and oncology applications, where laboratories required a connected path from sample preparation to variant interpretation. The system formed part of Qiagen’s effort to provide complete rather than component-only sequencing workflows.
Bioinformatics
QIAGEN Clinical Insights
QIAGEN Clinical Insights is a genomic interpretation and clinical decision-support offering. It helps users evaluate variants identified through sequencing and connect molecular findings with disease knowledge, published evidence and potential clinical relevance. Its capabilities were strengthened through acquisitions including N-of-One and Qiagen’s broader bioinformatics portfolio.

Marketing campaigns

2009H1N1 diagnostic response
Global
Qiagen released a clinically validated molecular diagnostic test for H1N1 influenza during the swine-flu outbreak, demonstrating the use of its assay-development capabilities in an urgent infectious-disease context.
Outcome. Expanded the company’s visibility in infectious-disease molecular diagnostics.
Source

Brand decisions

2023
Verogen acquisition announcedM&A
Background
Qiagen sought to extend its molecular-analysis portfolio into forensic and human-identification applications.
Action taken
Qiagen announced its intention to acquire Verogen, including GEDmatch.
Aftermath
The proposed transaction was expected to add forensic-genomics capabilities and a genetic-genealogy service to Qiagen’s portfolio.
Announced acquisition consideration. $150 million (January 2023)
Source
2022
BLIRT majority investmentM&A
Background
Qiagen wanted additional capabilities in recombinant enzymes and molecular-biology reagents.
Action taken
The company acquired a majority stake in BLIRT S.A.
Aftermath
The transaction added research, development and manufacturing capacity for customized and standardized enzymes and reagents.
Source
2020
Thermo Fisher takeover proposal rejectedM&A
Background
Thermo Fisher proposed acquiring Qiagen for €39 per share in cash, later increasing the offer to €43 after shareholder criticism that the initial price undervalued the company.
Action taken
Qiagen proceeded with the transaction process, but the offer was terminated on August 13 after only about 47% shareholder acceptance, below the required 66.6% threshold.
Aftermath
Qiagen remained independent, reimbursed approximately $95 million in specified Thermo Fisher expenses, and acquired the remaining NeuMoDx shares it did not already own.
Proposed transaction value and termination expense reimbursement. €39 per share initially; €43 per share after revision → Approximately $95 million reimbursement to Thermo Fisher (2020)
- Thermo Fisher Scientific — Thermo Fisher increased its offer but ended the transaction after the acceptance condition was not met.
Source
2019
Illumina diagnostic-development agreementStrategy
Background
Qiagen sought to expand its assay and companion-diagnostic reach while working with established sequencing-instrument platforms.
Action taken
Qiagen entered a non-exclusive agreement granting it rights to develop and globally commercialize in-vitro diagnostic kits for use with Illumina diagnostic instruments.
Aftermath
The agreement created a collaboration route between Qiagen assay development and Illumina diagnostic instrumentation.
Source
2018
QIAstat-Dx platform launchedProduct launch
Background
The acquisition of STAT-Dx gave Qiagen technology for automated multiplex molecular testing.
Action taken
Qiagen launched the QIAstat-Dx platform for syndromic molecular diagnostics.
Aftermath
The platform broadened Qiagen’s presence in automated clinical testing.
Source
2015
GeneReader NGS System introducedProduct launch
Background
Qiagen aimed to extend its sample-preparation and assay business into integrated sequencing workflows.
Action taken
The company launched the GeneReader next-generation sequencing system.
Aftermath
The launch increased Qiagen’s participation in targeted sequencing and oncology workflows.
Source
2011
Restructuring focused on personalized medicine and emerging marketsStrategy
Background
Qiagen sought to concentrate resources on areas it identified as higher-growth, including personalized healthcare and developing markets.
Action taken
The company announced internal restructuring and a workforce reduction affecting approximately 10% of its roughly 3,900 positions.
Aftermath
The program repositioned resources toward clinical and geographically expanding businesses.
Source

Recent events

2026.08.27
Reported2026.08.27
Anthropic launches Model Hardware Standard (MHS) for AI agents to control physical hardware[4]Anthropic发布面向AI智能体操控物理硬件的Model Hardware Standard（MHS）finance.sina.com.cn
Anthropic announced the Model Hardware Standard (MHS), a new standard that lets large-model-driven AI agents such as Claude safely and quickly operate physical devices including microscopes, robotic arms, liquid handlers and lasers. MHS was developed from a collaboration with the Howard Hughes Medical Institute (HHMI) Janelia Research Campus and is available as a research preview to a first group of research labs and advanced manufacturers. Hardware and software vendors including AWS, Automata, Danaher, Doosan Robotics, MBF Bioscience, QIAGEN, Tecan, Universal Robots, Hugging Face and Raspberry Pi are adding or testing MHS support.
2022.01.18
Reported2022.01.18
QIAGEN launches QIAwave kits[5]QIAGEN推出QIAwave试剂盒finanznachrichten.de
QIAGEN announced the launch of three QIAwave nucleic acid extraction kits, which use fewer components and produce less waste than existing kits.
2022.01.07
Reported2022.01.07
QIAGEN and Atila BioSystems collaborate on prenatal testing for QIAcuity[6]QIAGEN与Atila BioSystems合作开发适用于QIAcuity的产前检测news.europawire.eu
QIAGEN announced a collaboration with Atila BioSystems to provide non-invasive prenatal testing solutions for QIAGEN’s dPCR franchise and QIAcuity platform.
2022.01.07
Reported2022.01.07
QIAGEN and Actome enter QIAcuity licensing and co-marketing agreement[6]QIAGEN与Atila BioSystems合作开发适用于QIAcuity的产前检测news.europawire.eu
QIAGEN announced a co-exclusive licensing and co-marketing agreement with Actome that brings Actome’s PICO-Technology to QIAcuity for digital PCR protein analysis applications. The companies will jointly develop assays; QIAGEN also made an undisclosed investment in Actome as part of the agreement.
2021.06.29
Reported2021.06.29
QIAGEN and Verogen announce commercialization partnership[7]QIAGEN与Verogen宣布商业化合作finanznachrichten.de
QIAGEN announced a commercialization partnership with Verogen. The agreement gives QIAGEN global distribution rights to Verogen's human-identification portfolio, and the companies will also cooperate to commercialize forensic next-generation sequencing workflows.
2021.05.25
Reported2021.05.25
QIAGEN and Mirati collaborate on KRAS companion diagnostic[8]QIAGEN与Mirati合作开发KRAS伴随诊断finanznachrichten.de
QIAGEN announced a global collaboration with Mirati Therapeutics to continue developing a tissue-based KRAS companion diagnostic, initially focused on non-small cell lung cancer.
2021.04.21
QIAGEN and DiaSorin launch LIAISON LymeDetect Assay[9]QIAGEN与DiaSorin推出LIAISON LymeDetect检测selectscience.net
QIAGEN and DiaSorin announced the launch of the LIAISON LymeDetect Assay for markets accepting the CE mark. The assay is designed to aid detection of early Lyme borreliosis on LIAISON analyzer systems.
2021.04.20
Reported2021.04.20
QIAGEN launches artus SARS-CoV-2 Prep&Amp UM Kit[10]QIAGEN 推出 artus SARS-CoV-2 Prep&Amp UM Kitfinanznachrichten.de
QIAGEN announced the launch of its artus SARS-CoV-2 Prep&Amp UM Kit, a COVID-19 testing kit that combines sample preparation and detection. The kit was CE-IVD registered for use in the European Union and other markets; QIAGEN had submitted an application for U.S. Emergency Use Authorization.
2021.03.05
Reported2021.03.05
QIAGEN announces QIAsphere cloud-based solutions[11]QIAGEN 宣布推出 QIAsphere 云端解决方案finance.yahoo.com
QIAGEN announced the launch of QIAsphere cloud-based solutions for its QIAstat-Dx syndromic testing platform. The new platform will enable laboratories and QIAstat-Dx users to monitor tests and instrument status remotely.
2021.03.02
Reported2021.03.02
QIAGEN launches QIAcube Connect MDx[12]QIAGEN推出QIAcube Connect MDxfinanznachrichten.de
QIAGEN announced the global launch of QIAcube Connect MDx, an automated sample-processing platform for molecular diagnostic laboratories, available in the U.S. and Canada, the European Union and other markets worldwide.

Sources27 sources

Cite this profile: Cite the canonical profile. /brand-wiki/qiagen · Editorial policy · How profiles are compiled